BeOne Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for BeOne Medicines (ONC).

Price Target Range — 8 Quarters

Analyst Consensus — 16 Analysts

2S.Buy

14Buy

Consensus RatingBuy# Analysts16Avg. Consensus PT$387Upside to Avg. PT+7.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$425→$445
Sep 10, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$407→$415
Aug 6, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$424→$454
Aug 6, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$451→$450
Aug 6, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$416→$418
Aug 6, 2026	Guggenheim	Michael Schmitz	PT Raise	Buy	$420→$430
Aug 6, 2026	Barclays	Peter Lawson	PT Raise	Overweight	$403→$407
Aug 6, 2026	Citizens	Reni J. Benjamin	PT Raise	Market Outperform	$396→$405
Jul 23, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$415→$425
Jul 14, 2026	Barclays	Peter Lawson	PT Cut	Overweight	$409→$403
Jul 13, 2026	Jefferies	Faisal Khurshid	Upgrade	Hold→Buy	$333→$380
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$436→$451
Jul 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$413→$416
Jul 1, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$396
Jun 2, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$425→$436
May 15, 2026	Leerink Partners	—	PT Raise	Outperform	$364→$367
May 7, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$423→$425
May 7, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$410→$420
May 7, 2026	Barclays	Peter Lawson	PT Raise	Overweight	$405→$409
May 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$411→$413

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $425 to $445.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $407 to $415.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $424 to $454.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and lowers the price target from $451 to $450.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $416 to $418.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $430.

Benzinga Newsdesk

BeOne Medicines Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

BeOne Medicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445

PRO
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

PRO
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

PRO
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

PRO
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

People Also Watch

People Also Watch

BeOne Medicines Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

BeOne Medicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445

PROBarclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

PROTD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

PRORBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

PROTruist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

PROGuggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445

PRO
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

PRO
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

PRO
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

PRO
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430